The FDA released a second tranche of Commissioner’s National Priority Vouchers (CNPVs), adding six drugs to the program designed to speed review and support domestic priorities. The second round included high‑profile obesity candidates from major drugmakers, signaling regulatory backing for fast‑tracking therapies tied to U.S. health priorities. The announcement coincided with White House pricing agreements with Novo Nordisk and Eli Lilly to expand access to GLP‑1 therapies, underscoring a policy push that blends accelerated review incentives with price concessions. Industry players are recalibrating launch and regulatory strategies in response to the combined voucher and pricing signals.